Concepedia

G.S. Mason

GM

16

Publications

1.3K

Citations

15

H-Index

1991

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

MSD (UK) Limited (United Kingdom)

G.S. Mason is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and neuropharmacology.

Top concepts

Publications per year

1991–2010

16

Publications

16

Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn

S. Boyce, A. C. Wyatt, J.K. Webb et al. · Neuropharmacology · 1999 · 336 citations

, , +14

The novel NK1 receptor antagonist MK–0869 (L–754,030) and its water soluble phosphoryl prodrug, L–758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets

F.D. Tattersall, Wayne Rycroft, M. Cumberbatch et al. · Neuropharmacology · 2000 · 136 citations

, , +7

Possible Antimigraine Mechanisms of Action of the 5HT<sub>1F</sub> Receptor Agonist LY334370

Sara L. Shepheard, Lars Edvinsson, M. Cumberbatch et al. · Cephalalgia · 1999 · 113 citations

, , +22

Dural vasodilation causes a sensitization of rat caudal trigeminal neurones <i>in vivo</i> that is blocked by a 5‐HT<sub>1B/1D</sub> agonist

M. Cumberbatch, David J. Williamson, G.S. Mason et al. · British Journal of Pharmacology · 1999 · 94 citations · Full text

Substance P (Neurokinin 1) Receptor Antagonists Enhance Dorsal Raphe Neuronal Activity

Rachel K. Conley, M. Cumberbatch, G.S. Mason et al. · Journal of Neuroscience · 2002 · 81 citations · Full text

, , +16

Rows per page

1–5 of 16